We studied and compared the effects of GS967 (1 µM) to those of the class I/B antiarrhythmic drug mexiletine (40 µM) on ICa, INaL and INaP in canine ventricular myocardium by combining the conventional microelectrode, voltage clamp and action potential voltage clamp techniques. It was found that GS967, which is generally considered as a selective blocker of INaL[16], inhibits ICa and INaP as well, similarly to the class I/B antiarrhythmic drug mexiletine[33] but with higher potency. The ICa blocking effects were more prominent under action potential voltage clamp than under conventional voltage clamp conditions in the case of both drugs (compare Figs. 2 and 4). The reason for this difference is unknown at present, however, it highlights the advantage of the action potential voltage clamp technique in cardiac cellular electrophysiology and pharmacology.
Based on the hypothetically selective INaL blocker nature of GS967, the drug was previously mentioned as a novel class VI antiarrhythmic agent[43]. However, without questioning the theoretical possibility of the concept for selective INaL inhibition, an alternative approach should also be considered, since the concept whether INaL can be blocked selectively is an interesting and still unresolved issue. There is evidence that sodium current in cardiac tissues may also be conducted by sodium channels other than the cardiac specific Nav1.5 channels, such as Nav1.8[44]. Also, relatively high mRNA expression levels of Nav2.1 were reported in human ventricle[45] but proper functional evidence for its role is still lacking. If these channels play a role in INaL but not in INaP, pharmacological inhibition of these channels may result in selective INaL blockade. However, GS967 has not been shown to inhibit these latter types of sodium channels but it was reported to inhibit cardiac type Nav1.5 channels[9, 10]. Nav1.5 channels have complex and multiple open and closed states[46] with different drug binding properties governing active, inactive and resting channel states. Accordingly, drugs interacting with the binding sites of the channels depending on their actual open or closed channel states may produce variable effects on INaP and INaL. For example, when a drug binds rapidly and with high affinity to open and inactivated channel states, and it dissociates rapidly from closed resting channel states, it would not inhibit INaP but INaL. This would be due to complete drug dissociation from its binding site in the resting closed states unless frequency was very high or at least the cycle length would be shorter than its dissociation from the channel. Consequently, whether a drug inhibits INaP or INaL selectively or both of them, largely depends on the stimulation protocol but not on existing specific INaP or INaL binding sites. Present results and other recently published data[9, 10] are consistent with this suggestion and do not support a mechanism which is based on specific INaL inhibition that is distinctly different from class I/B antiarrhythmic actions described for drugs such as mexiletine[14, 46], lidocaine[9, 10, 14], amiodarone[11] and ranolazine[47]. This approach is also in line with the reported high (38-fold) selectivity of ranolazine on INaL over INaP[2], which is intermediate (13-fold) for amiodarone[3] and much lower (only 3-fold) for flecainide[48].
In our experiments, both GS967 and mexiletine significantly depressed V+ max at high stimulation rates. It was previously established that changes of V+ max and INaP are not linear and a relatively modest decrease of V+ max can represent robust depression of INaP[35, 36]. Accordingly, the 20–30% reduction of V+ max measured in the present study in papillary muscle preparations (at pacing cycle lengths of 0.3–0.4 s) following GS967 and mexiletine application can represent a similar degree of INaP depression as the measured 60–80% reduction of INaL obtained in ventricular myocytes. Therefore, in theory, neither GS967 nor mexiletine can be considered as “selective” INaL inhibitors. However, when therapy is concerned – assuming that decreased INaP is proarrhythmic, while reduced INaL is antiarrhythmic – GS967, which has about 3-fold faster offset kinetics, can be more beneficial than mexiletine since INaP would be affected in a lesser extent than INaL by GS967 at normal or moderately enhanced heart rates.
On the basis of present and other results it is clear that GS967 affects INaP in a strongly rate- and moderately species-dependent fashion. Similarly to our results, V+ max was reduced by 0.3 µM GS967 in murine myocytes[49], while the same concentration of the drug failed to modify V+ max in canine Purkinje strands[50]. On the other hand, GS967 shortened APD in a variety of preparations, including rat[51, 52], murine[49], rabbit[16, 53] and human[54] ventricular cells within a wide concentration range (0.1-1 µM) – similarly to the present observations in isolated canine ventricular cells. In our multicellular preparations, however, a significant APD shortening effect appeared only at cycle lengths longer than 1.5 s. This can be explained by the well-known higher drug-sensitivity of single cells comparing to multicellular preparations. The moderate reduction of ICa by GS967, in addition to its decrease of INaL, is not expected to impair A-V conduction. However, this effect can contribute to the GS967-induced shortening of the elongated APD, reduction of the enhanced dispersion and short term variability of repolarization, changes often preceding torsade de pointes arrhythmias[38–40].
Taken together the present results and the literature, it is likely that a compound having kinetic properties similar to GS967 would be a very promising new antiarrhythmic agent, since several in vitro[16–19, 49–54] and in vivo[51, 55] studies support the potent antiarrhythmic activity of GS967. Its kinetic properties are better than those of mexiletine, as shown in this study, and also than those of ranolazine[9], agents known to suppress INaL. Although GS967 had high brain penetration and caused a profound use-dependent block on all sodium channel isoforms studied, making the compound prone for possible central nervous system side effects[56], a new agent exhibiting the same kinetic properties of GS967 without CNS side effects would represent a promising candidate for future development.
In summary, GS967 – similarly to mexiletine – inhibited both the peak and late components of Na+ current, suppressed Ca2+ current and decreased beat-to-beat variability of APD. Based on its kinetic properties, GS967 should be classified as a new potent class I/B (or probably I/B + IV) antiarrhythmic agent. The results of the present study also suggest that investigations of “selective” INaL inhibitors should be carried out through a wide range of stimulation rates since the effect of drugs like GS967 or mexiletine, that possess fast offset kinetics of INaP inhibition, can be misinterpreted.